Abstract
Ocular symptoms and signs are the most common clinical manifestation of myasthenia gravis (MG). Paradoxically, however, the ocular aspects of myasthenia are the least well studied and understood. We even lack good clinical outcome measures that might be used to quantify disease severity and impact on patient-reported outcome measures. In this chapter we discuss possible explanations for the predilection for ocular involvement in MG, the protean clinical manifestations of ocular disease, the challenges associated with reaching a confident diagnosis, and the risk of progression to generalized disease. With the exception of a small recent study of steroids in ocular myasthenia, clinical trials typically exclude ocular myasthenia patients. The result is uncertainty about important clinical questions such as the value of steroids and other immunosuppressive agents in mitigating the risk of progression to generalized disease and the uncertain role of thymectomy in the overall treatment of ocular myasthenia.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 101-112 |
| Number of pages | 12 |
| Journal | Current Clinical Neurology |
| DOIs | |
| State | Published - Jan 1 2018 |
| Externally published | Yes |
Fingerprint
Keywords
- Ocular myasthenia
- Ophthalmoplegia
- Ptosis Diplopia
ASJC Scopus subject areas
- Clinical Neurology
Cite this
Ocular myasthenia. / Wong, Sui Hsien; Benatar, Michael.
In: Current Clinical Neurology, 01.01.2018, p. 101-112.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Ocular myasthenia
AU - Wong, Sui Hsien
AU - Benatar, Michael
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Ocular symptoms and signs are the most common clinical manifestation of myasthenia gravis (MG). Paradoxically, however, the ocular aspects of myasthenia are the least well studied and understood. We even lack good clinical outcome measures that might be used to quantify disease severity and impact on patient-reported outcome measures. In this chapter we discuss possible explanations for the predilection for ocular involvement in MG, the protean clinical manifestations of ocular disease, the challenges associated with reaching a confident diagnosis, and the risk of progression to generalized disease. With the exception of a small recent study of steroids in ocular myasthenia, clinical trials typically exclude ocular myasthenia patients. The result is uncertainty about important clinical questions such as the value of steroids and other immunosuppressive agents in mitigating the risk of progression to generalized disease and the uncertain role of thymectomy in the overall treatment of ocular myasthenia.
AB - Ocular symptoms and signs are the most common clinical manifestation of myasthenia gravis (MG). Paradoxically, however, the ocular aspects of myasthenia are the least well studied and understood. We even lack good clinical outcome measures that might be used to quantify disease severity and impact on patient-reported outcome measures. In this chapter we discuss possible explanations for the predilection for ocular involvement in MG, the protean clinical manifestations of ocular disease, the challenges associated with reaching a confident diagnosis, and the risk of progression to generalized disease. With the exception of a small recent study of steroids in ocular myasthenia, clinical trials typically exclude ocular myasthenia patients. The result is uncertainty about important clinical questions such as the value of steroids and other immunosuppressive agents in mitigating the risk of progression to generalized disease and the uncertain role of thymectomy in the overall treatment of ocular myasthenia.
KW - Ocular myasthenia
KW - Ophthalmoplegia
KW - Ptosis Diplopia
UR - http://www.scopus.com/inward/record.url?scp=85065811488&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065811488&partnerID=8YFLogxK
U2 - 10.1007/978-3-319-73585-6_7
DO - 10.1007/978-3-319-73585-6_7
M3 - Article
AN - SCOPUS:85065811488
SP - 101
EP - 112
JO - Current Clinical Neurology
JF - Current Clinical Neurology
SN - 1559-0585
ER -